Positive outcomes for Promus Element in Platinum China study


Boston Scientific has announced that the Platinum China study, which was presented at China Interventional Therapeutics (20–23 March, Beijing, China), indicated that the Promus Element stent is associated with a low rate of stent thrombosis at nine months. These data support the existing safety and efficacy data for the stent.

According to a company press release, the Platinum China study—a separate arm of the overall Platinum trial programme—demonstrated a low nine-month ARC definite/probable stent thrombosis rate of 0% and a 2.2% nine-month target lesion revascularisation rate with the Promus Element stent.

The principal investigator of the trial is Gao Runlin from Fuwai Hospital, National Center for Cardiovascular Disease of China, and a member of the Chinese Academy of Engineering, and Han Yaling, a renowned cardiovascular expert from Shenyang Northern General Hospital, was the co-lead researcher and co-principal investigator.

Michael F. Mahoney, chief executive officer of Boston Scientific, said: “As an innovative global leader in the field of coronary intervention, Boston Scientific is dedicated to providing a wide range of high-quality and efficient solutions for customers and patients in China.”